# begin document GENTLE_medical_transplant
0	Description	(abstract-1)
1	:	_
2	Posttransplant	(abstract-2-Post%2Dtransplant_lymphoproliferative_disorder
3	lymphoproliferative	_
4	disorder	abstract-2-Post%2Dtransplant_lymphoproliferative_disorder)
5	,	_
6	chronic	(abstract-3
7	renal	(object-4)
8	insufficiency	abstract-3)
9	,	_
10	squamous	(abstract-5(animal-6
11	cell	animal-6)
12	carcinoma	_
13	of	_
14	the	(object-7
15	skin	abstract-5)object-7)
16	,	_
17	anemia	(abstract-8
18	secondary	_
19	to	_
20	chronic	(abstract-3
21	renal	(object-4)
22	insufficiency	abstract-3)
23	and	_
24	chemotherapy	(event-9)abstract-8)
25	,	_
26	and	_
27	hypertension	(abstract-10)
28	.	_
29	The	(person-11
30	patient	person-11)
31	is	_
32	here	_
33	for	_
34	followup	(event-12
35	visit	event-12)
36	and	_
37	chemotherapy	(event-9)
38	.	_
39	CHIEF	(abstract-13
40	COMPLAINT	abstract-13)
41	:	_
42	The	(person-11
43	patient	person-11)
44	is	_
45	here	_
46	for	_
47	followup	(event-12
48	visit	event-12)
49	and	_
50	chemotherapy	(event-9)
51	.	_
52	DIAGNOSES	(abstract-14)
53	:	_
54	1.	_
55	Posttransplant	(abstract-2-Post%2Dtransplant_lymphoproliferative_disorder
56	lymphoproliferative	_
57	disorder	abstract-2-Post%2Dtransplant_lymphoproliferative_disorder)
58	.	_
59	2.	_
60	Chronic	(abstract-3
61	renal	_
62	insufficiency	abstract-3)
63	.	_
64	3.	(abstract-15
65	Squamous	(abstract-5(animal-6
66	cell	animal-6)
67	carcinoma	_
68	of	_
69	the	(object-7
70	skin	abstract-15)abstract-5)object-7)
71	.	_
72	4.	_
73	Anemia	(abstract-8
74	secondary	_
75	to	_
76	chronic	(abstract-3
77	renal	(object-4)
78	insufficiency	abstract-3)
79	and	_
80	chemotherapy	(event-9)abstract-8)
81	.	_
82	5.	_
83	Hypertension	(abstract-10)
84	.	_
85	HISTORY	(abstract-16
86	OF	_
87	PRESENT	(abstract-17
88	ILLNESS	abstract-16)abstract-17)
89	:	_
90	A	(person-11
91	51	_
92	-	_
93	year	_
94	-	_
95	old	_
96	white	_
97	male	_
98	diagnosed	_
99	with	_
100	PTLD	(abstract-2-Post%2Dtransplant_lymphoproliferative_disorder)
101	in	_
102	latter	(time-18
103	half	_
104	of	_
105	2007	(time-19)person-11)time-18)
106	.	_
107	He	(person-11)
108	presented	_
109	with	_
110	symptoms	(abstract-20
111	of	_
112	increasing	(abstract-21
113	adenopathy	abstract-20)abstract-21)
114	,	_
115	abdominal	(abstract-22
116	pain	abstract-22)
117	,	_
118	weight	(abstract-23(abstract-24)
119	loss	abstract-23)
120	,	_
121	and	_
122	anorexia	(abstract-25)
123	.	_
124	He	(person-11)
125	did	_
126	not	_
127	seek	_
128	medical	(abstract-26
129	attention	abstract-26)
130	immediately	_
131	.	_
132	He	(person-11)
133	was	_
134	finally	_
135	hospitalized	_
136	by	_
137	the	_
138	renal	(abstract-27(event-28(object-4)
139	transplant	event-28)
140	service	abstract-27)
141	and	_
142	underwent	_
143	a	(event-29
144	lymph	(object-30
145	node	object-30)
146	biopsy	_
147	in	_
148	the	(object-31
149	groin	object-31)
150	,	_
151	which	_
152	showed	_
153	diagnosis	(abstract-32
154	of	_
155	large	(object-33
156	cell	_
157	lymphoma	event-29)abstract-32)object-33)
158	.	_
159	He	(person-11)
160	was	_
161	discussed	_
162	at	_
163	the	(event-34
164	hematopathology	(abstract-35)
165	conference	event-34)
166	.	_
167	Chemotherapy	(event-9
168	with	_
169	rituximab	(substance-36)
170	plus	_
171	cyclophosphamide	(substance-37)
172	,	_
173	daunorubicin	(substance-38)
174	,	_
175	vincristine	(substance-39)
176	,	_
177	and	_
178	prednisone	(substance-40)event-9)
179	was	_
180	started	_
181	.	_
182	First	(abstract-41
183	cycle	_
184	of	_
185	chemotherapy	(event-9)abstract-41)
186	was	_
187	complicated	_
188	by	_
189	sepsis	(abstract-42)
190	despite	_
191	growth	(abstract-43(abstract-44
192	factor	abstract-44)
193	support	abstract-43)
194	.	_
195	He	(person-11)
196	also	_
197	appeared	_
198	to	_
199	have	_
200	become	_
201	disoriented	_
202	either	_
203	secondary	_
204	to	_
205	sepsis	(abstract-42)
206	or	_
207	steroid	(abstract-45(substance-46)
208	therapy	abstract-45)
209	.	_
210	The	(person-11
211	patient	person-11)
212	has	_
213	received	_
214	5	(abstract-47
215	cycles	_
216	of	_
217	chemotherapy	(event-9)abstract-47)
218	to	_
219	date	_
220	.	_
221	He	(person-11)
222	did	_
223	not	_
224	keep	_
225	his	(event-48(person-11)
226	appointment	_
227	for	_
228	a	(abstract-49
229	PET	(abstract-50)
230	scan	abstract-49)
231	after	_
232	3	(abstract-51
233	cycles	event-48)abstract-51)
234	because	_
235	he	(person-11)
236	was	_
237	not	_
238	feeling	_
239	well	_
240	.	_
241	His	(abstract-52(person-11)
242	therapy	abstract-52)
243	has	_
244	been	_
245	interrupted	_
246	for	_
247	infection	(event-53
248	related	_
249	to	_
250	squamous	(abstract-5(animal-6
251	cell	animal-6)
252	cancer	event-53)abstract-5)
253	,	_
254	skin	(event-54(object-7)
255	surgery	event-54)
256	as	_
257	well	_
258	as	_
259	complaints	(event-55
260	of	_
261	chest	(object-56)
262	infection	event-55)
263	.	_
264	The	(person-11
265	patient	person-11)
266	is	_
267	here	(place-57)
268	for	_
269	the	(abstract-58
270	sixth	_
271	and	_
272	final	_
273	cycle	_
274	of	_
275	chemotherapy	(event-9)abstract-58)
276	.	_
277	He	(person-11)
278	states	_
279	he	(person-11)
280	feels	_
281	well	_
282	.	_
283	He	(person-11)
284	denies	_
285	any	(abstract-59
286	nausea	(abstract-60)abstract-59)
287	,	_
288	vomiting	(event-61)
289	,	_
290	cough	(event-62)
291	,	_
292	shortness	(abstract-63
293	of	_
294	breath	(abstract-64)abstract-63)
295	,	_
296	chest	(abstract-65(object-56)
297	pain	abstract-65)
298	or	_
299	fatigue	(abstract-66)
300	.	_
301	He	(person-11)
302	denies	_
303	any	(abstract-67
304	tingling	_
305	or	_
306	numbness	_
307	in	_
308	his	(object-68(person-11)
309	fingers	abstract-67)object-68)
310	.	_
311	Review	(abstract-69
312	of	_
313	systems	(abstract-70)abstract-69)
314	is	_
315	otherwise	_
316	entirely	_
317	negative	_
318	.	_
319	Performance	(abstract-71
320	status	_
321	on	_
322	the	(abstract-72
323	ECOG	_
324	scale	abstract-71)abstract-72)
325	is	_
326	1	(abstract-71)
327	PHYSICAL	(abstract-73
328	EXAMINATION	abstract-73)
329	:	_
330	VITAL	(abstract-74
331	SIGNS	abstract-74)
332	:	_
333	He	(person-11)
334	is	_
335	afebrile	_
336	.	_
337	Blood	(abstract-75(substance-76)
338	pressure	abstract-75)
339	161	(abstract-75
340	/	_
341	80	abstract-75)
342	,	_
343	pulse	(abstract-77)
344	65	(abstract-77)
345	,	_
346	weight	(abstract-24)
347	71.5	(abstract-24
348	kg	abstract-24)
349	,	_
350	which	_
351	is	_
352	essentially	_
353	unchanged	_
354	from	_
355	his	(event-78(person-11)
356	prior	_
357	visit	event-78)
358	.	_
359	There	_
360	is	_
361	mild	(abstract-79
362	pallor	abstract-79)
363	noted	_
364	.	_
365	There	_
366	is	_
367	no	_
368	icterus	(abstract-80)
369	,	_
370	adenopathy	(abstract-21)
371	or	_
372	petechiae	(object-81)
373	noted	_
374	.	_
375	CHEST	(object-56)
376	:	_
377	Clear	_
378	to	_
379	auscultation	(event-82)
380	.	_
381	CARDIOVASCULAR	(abstract-83)
382	:	_
383	S1	(abstract-84)
384	and	_
385	S2	(abstract-85)
386	normal	_
387	with	_
388	regular	(event-86
389	rate	_
390	and	_
391	rhythm	event-86)
392	.	_
393	Systolic	(event-87
394	flow	_
395	murmur	event-87)
396	is	_
397	best	_
398	heard	_
399	in	_
400	the	(place-88
401	pulmonary	_
402	area	place-88)
403	.	_
404	ABDOMEN	(object-89)
405	:	_
406	Soft	_
407	and	_
408	nontender	_
409	with	_
410	no	_
411	organomegaly	(event-90)
412	.	_
413	Renal	(event-28(object-4)
414	transplant	event-28)
415	is	_
416	noted	_
417	in	_
418	the	(object-91
419	right	_
420	lower	_
421	quadrant	object-91)
422	with	_
423	a	(object-92
424	scar	object-92)
425	present	_
426	.	_
427	EXTREMITIES	(abstract-93)
428	:	_
429	Reveal	_
430	no	(abstract-94
431	edema	abstract-94)
432	.	_
433	LABORATORY	(abstract-95
434	DATA	abstract-95)
435	:	_
436	CBC	(abstract-96(abstract-97-Complete_blood_count)
437	from	_
438	today	(time-98)abstract-96)
439	shows	_
440	white	(abstract-99
441	count	_
442	of	_
443	9.6	(abstract-99)
444	with	_
445	a	(abstract-100
446	normal	_
447	differential	abstract-99)abstract-100)
448	,	_
449	ANC	(abstract-101)
450	of	_
451	7400	(abstract-101)
452	,	_
453	hemoglobin	(abstract-102)
454	8.9	(abstract-102)
455	,	_
456	hematocrit	(abstract-103)
457	26.5	(abstract-103)
458	with	_
459	an	(abstract-104
460	MCV	_
461	of	_
462	109	(abstract-104)abstract-104)
463	,	_
464	and	_
465	platelet	(abstract-105(object-106)
466	count	_
467	of	_
468	220,000	(abstract-105)abstract-105)
469	.	_
470	ASSESSMENT	(abstract-107)
471	AND	_
472	PLAN	(abstract-108)
473	:	_
474	1.	_
475	Diffuse	_
476	large	(object-33
477	B	(object-109
478	-	_
479	cell	object-109)
480	lymphoma	object-33)
481	following	_
482	transplantation	(event-110)
483	.	_
484	The	(person-11
485	patient	person-11)
486	is	_
487	to	_
488	receive	_
489	his	(abstract-111(person-11)
490	sixth	_
491	and	_
492	final	_
493	cycle	_
494	of	_
495	chemotherapy	(event-9)abstract-111)
496	today	(time-98)
497	.	_
498	PET	(abstract-49(abstract-50)
499	scan	abstract-49)
500	has	_
501	been	_
502	ordered	_
503	to	_
504	be	_
505	done	_
506	within	_
507	2	(time-112
508	weeks	time-112)
509	.	_
510	He	(person-11)
511	will	_
512	see	_
513	me	(person-113)
514	back	_
515	for	_
516	the	(event-114
517	visit	_
518	in	_
519	3	(time-115
520	weeks	event-114)time-115)
521	with	_
522	CBC	(abstract-97-Complete_blood_count)
523	,	_
524	CMP	(abstract-116-Comprehensive_metabolic_panel)
525	,	_
526	and	_
527	LDH	(abstract-117-Lactate_dehydrogenase)
528	.	_
529	2.	_
530	Chronic	(abstract-3
531	renal	_
532	insufficiency	abstract-3)
533	.	_
534	3.	_
535	Anemia	(abstract-8
536	secondary	_
537	to	_
538	chronic	(event-118
539	renal	(object-4)
540	failure	event-118)
541	and	_
542	chemotherapy	(event-9)abstract-8)
543	.	_
544	He	(person-11)
545	is	_
546	to	_
547	continue	_
548	on	_
549	his	(abstract-119(person-11)
550	regimen	_
551	of	_
552	growth	(abstract-43(abstract-44
553	factor	abstract-44)
554	support	abstract-119)abstract-43)
555	.	_
556	4.	_
557	Hypertension	(abstract-10)
558	.	_
559	This	(abstract-10)
560	is	_
561	elevated	_
562	today	(time-98)
563	because	_
564	he	(event-120(person-11)
565	held	_
566	his	(substance-121(person-11)
567	meds	substance-121)
568	because	_
569	he	(person-11)
570	is	_
571	getting	_
572	rituximab	(substance-122)event-120)
573	other	_
574	than	_
575	that	(event-120)
576	this	(abstract-10)
577	is	_
578	well	_
579	controlled	_
580	.	_
581	His	(abstract-116-Comprehensive_metabolic_panel(person-11)
582	CMP	abstract-116-Comprehensive_metabolic_panel)
583	is	_
584	pending	_
585	from	_
586	today	(time-98)
587	.	_
588	5.	_
589	Squamous	(abstract-5(abstract-5(animal-6
590	cell	animal-6)
591	carcinoma	abstract-5)
592	of	_
593	the	(object-7
594	skin	abstract-5)object-7)
595	.	_
596	The	(object-123
597	scalp	object-123)
598	is	_
599	well	_
600	healed	_
601	.	_
602	He	(person-11)
603	still	_
604	has	_
605	an	(object-124
606	open	_
607	wound	_
608	on	_
609	the	(object-125
610	right	_
611	posterior	_
612	aspect	_
613	of	_
614	his	(object-126(person-11)
615	trunk	object-124)object-125)object-126)
616	.	_
617	This	(object-124)
618	has	_
619	no	_
620	active	(abstract-127
621	drainage	abstract-127)
622	,	_
623	but	_
624	it	(object-124)
625	is	_
626	yet	_
627	to	_
628	heal	_
629	.	_
630	This	(object-124)
631	probably	_
632	will	_
633	heal	_
634	by	_
635	secondary	(abstract-128
636	intention	abstract-128)
637	once	_
638	chemotherapy	(event-9)
639	is	_
640	finished	_
641	.	_
642	Prescription	(substance-129
643	for	_
644	prednisone	(substance-130)
645	as	_
646	part	_
647	of	_
648	his	(event-9(person-11)
649	chemotherapy	substance-129)event-9)
650	has	_
651	been	_
652	given	_
653	to	_
654	him	(person-11)
655	.	_
# end document

